source
- J&J to acquire Ollin Biosciences for up to $3.3 billion, adding eye disease drug to its portfolioJohnson & Johnson announced it will purchase Ollin Biosciences, a biotechnology startup developing an eye disease therapy. The transaction includes an upfront payment of $2.2 billion and up to $1.…
- Johnson & Johnson agrees to acquire eye-disease biotech Ollin Biosciences for up to $3.3 billionJohnson & Johnson announced Monday that it will purchase Ollin Biosciences, a biotech focused on eye diseases. The transaction is valued at up to $3.3 billion, representing one of the larger recen…